Daniel S La

Summary

Affiliation: Amgen Inc
Country: USA

Publications

  1. ncbi Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis
    Daniel S La
    Department of Medicinal Chemistry, Amgen Inc, One Kendall Square, Cambridge, MA 02139, USA
    J Med Chem 51:1695-705. 2008
  2. ncbi Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation
    Jean Christophe Harmange
    Department of Medicinal Chemistry, Amgen Inc, One Kendall Square, Cambridge, MA 02139, USA
    J Med Chem 51:1649-67. 2008
  3. ncbi Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors
    Matthew M Weiss
    Department of Medicinal Chemistry, Amgen Inc, One Kendall Square, Cambridge, MA 02139, USA
    J Med Chem 51:1668-80. 2008
  4. ncbi Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors
    Emily A Peterson
    Medicinal Chemistry, Amgen Inc, 360 Binney St, Cambridge, MA 02142, USA
    Bioorg Med Chem Lett 22:4967-74. 2012

Detail Information

Publications4

  1. ncbi Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis
    Daniel S La
    Department of Medicinal Chemistry, Amgen Inc, One Kendall Square, Cambridge, MA 02139, USA
    J Med Chem 51:1695-705. 2008
    ..In addition, this series of molecules is typically well-absorbed orally, further demonstrating the 2,3-dihydro-1,4-benzoxazine moiety as a promising platform for generating kinase-based antiangiogenic therapeutic agents...
  2. ncbi Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation
    Jean Christophe Harmange
    Department of Medicinal Chemistry, Amgen Inc, One Kendall Square, Cambridge, MA 02139, USA
    J Med Chem 51:1649-67. 2008
    ..A full account of the preparation, structure-activity relationships, pharmacokinetic properties, and pharmacology of analogues within this series is presented...
  3. ncbi Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors
    Matthew M Weiss
    Department of Medicinal Chemistry, Amgen Inc, One Kendall Square, Cambridge, MA 02139, USA
    J Med Chem 51:1668-80. 2008
    ..Once-daily oral administration of 22 for 14 days led to 85% inhibition of established HT29 colon cancer and Calu-6 lung cancer xenografts at doses of 10 and 20 mg/kg, respectively...
  4. ncbi Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors
    Emily A Peterson
    Medicinal Chemistry, Amgen Inc, 360 Binney St, Cambridge, MA 02142, USA
    Bioorg Med Chem Lett 22:4967-74. 2012
    ....